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Abstract
Background: Traumatic brain injury (TBI) is a worldwide leading cause of mortality and disability. Among TBI
complications, agitation is a frequent behavioural problem. Agitation causes potential harm to patients and
caregivers, interferes with treatments, leads to unnecessary chemical and physical restraints, increases hospital
length of stay, delays rehabilitation, and impedes functional independence. Pharmacological treatments are often
considered for agitation management following TBI. Several types of agents have been proposed for the treatment
of agitation. However, the benefit and safety of these agents in TBI patients as well as their differential effects and
interactions are uncertain. In addition, animal studies and observational studies have suggested impaired cognitive
function with the use of certain antipsychotics and benzodiazepines. Hence, a safe and effective treatment for
agitation, which does not interfere with neurological recovery, remains to be identified.
Methods/design: With the help of Health Sciences librarian, we will design a search strategy in the following
databases: PubMed, Ovid MEDLINE®, EMBASE, CINAHL, PsycINFO, Cochrane Library, Google Scholar, Directory of
Open Access Journals, LILACS, Web of Science, and Prospero. A grey literature search will be performed using the
resources suggested in CADTH’s Grey Matters. We will include all randomized controlled, quasi-experimental, and
observational studies with control groups. The population of interest is all patients, including children and adults,
who have suffered a TBI. We will include studies in which agitation, not further defined, was the presenting
symptom or one of the presenting symptoms. We will also include studies where agitation was not the presenting
symptom but was measured as an outcome variable and studies assessing the safety of these pharmacological
interventions in TBI patients. We will include studies evaluating all pharmacological interventions including beta-
adrenergic blockers, typical and atypical antipsychotics, anticonvulsants, dopamine agonists, psychostimulants,
antidepressants, alpha-2-adrenergic agonists, hypnotics, and anxiolytics.
Discussion: Although agitation is frequent following TBI and pharmacological agents that are often used, there is
no consensus on the most efficacious and safest strategy to treat these complications. There is a need for an
updated systematic review to summarize the evidence in order to inform practice and future research.
Systematic review registration: PROSPERO CRD42016033140
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Background
Description of the condition
Traumatic brain injury (TBI) is a leading cause of mortal-
ity and disability worldwide. In the USA alone, approxi-
mately 50,000 people die each year from TBI and more
than 5 million live with TBI-related disabilities [1, 2]. TBI
induces focal injuries as well as vascular, haemorrhagic,
inflammatory, and cytotoxic injuries [3]. Among TBI
complications, agitation is a frequent behavioural problem
[4, 5]. Inattention, memory deficits, and disorientation are
consequences of TBI that may contribute to agitation [5].
Agitation has been defined as a state of confusion during
the period of impaired consciousness which follows the
initial injury, also termed post-traumatic amnesia, and is
characterized by excessive behaviours such as emotional
unrest, akathisia, impulsivity, disorganized thinking or
disinhibition, and aggression [6]. Agitation is reported in
20–41% of patients during the early stage of recovery in
acute care units and in up to 70% of patients in rehabilita-
tion units [5, 7–12]. Neurotransmitter imbalances (i.e., glu-
tamate, gamma-aminobutyric acid (GABA), dopamine,
acetylcholine, serotonin) are among the potential causes as
well as imbalances in the autonomic nervous system that
can lead to a paroxysmal sympathetic hyperactivity (PSH)
[3, 13]. Suspected risk factors for agitation following TBI in-
clude environmental stimuli, age, pain, infection, disrupted
sleep patterns, and frontal lobe damage [4, 5, 14–16].
Agitation causes potential harm to patients and care-
givers, interferes with treatments, leads to unnecessary
chemical and physical restraints, increases hospital length
of stay, delays rehabilitation, and impedes functional
independence [9–11, 16–18]. In the literature, several
terms have been used to describe altered states of cogni-
tion following TBI (i.e., delirium, confusion, encephalop-
athy), of which agitation is a common feature [3, 19–22].
Description of the intervention
Pharmacological treatments are often considered for agi-
tation management following TBI [23–25]. In acutely ill
patients, one recent single-centre study (n = 195
patients) reported antipsychotic use in 26.7% of patients
within 7 days of TBI [26]. In a recent observational
study of 10 North American inpatient rehabilitation
facilities, antidepressants, anticonvulsants, stimulants,
and antipsychotics were used for the management of
neurobehavioral complications of TBI in 67%, 47%, 28%,
and 25% of patients, respectively [27]. In addition, surveys
have suggested wide variations in practice patterns in regard
to the choice of agents to treat neurobehavioral problems
[24, 28]. Several types of agents have been proposed for the
treatment of agitation including antipsychotics, beta-
blockers, benzodiazepines, anticonvulsants, neurostimulants,
alpha-2 receptor agonists, and antidepressants (e.g., selective
serotonin reuptake inhibitors (SSRI), serotonin and
norepinephrine reuptake inhibitors (SNRI), norepinephrine
and dopamine reuptake inhibitors (NDRI), tricyclic antide-
pressants (TCA)). The benefit and safety of these agents in
TBI patients as well as their differential effects and interac-
tions are uncertain [29]. Thus, the long-term effects on
functional recovery and cognitive capacities are not well
studied. In addition, animal studies and observational stud-
ies have suggested impaired cognitive function with the use
of certain antipsychotics and benzodiazepines [26, 30–34].
Hence, a safe and effective treatment for agitation, which
does not interfere with neurological recovery, remains to be
identified [29].
How the intervention might work
TBI is associated with an imbalance in the autonomic ner-
vous system, which may lead to an increase in sympathetic
activity, termed paroxysmal sympathetic hyperactivity
(PSH) [35]. PSH has been defined as “a syndrome,
recognized in a subgroup of survivors of severe acquired
brain injury, of simultaneous, paroxysmal transient in-
creases in sympathetic (elevated heart rate, blood pressure,
respiratory rate, temperature, sweating), and motor (pos-
turing) activity” [13]. PSH is suspected to be involved in
the mechanism of post-traumatic agitation [35, 36]. The
pathophysiology and clinical trial evidence suggest that
lipophilic beta-blockers such as propranolol may offer
benefit by reducing hyperadrenergic activity [15, 23, 37].
Alternatively, by inhibiting the release of norepinephrine
at the presynaptic alpha-2 receptors, clonidine and dex-
medetomidine may also prove beneficial [37, 38].
The widely used first generation antipsychotics inhibit
dopamine transmission in the mesolimbic and mesocortical
systems in the brain, which is thought to be responsible for
their effect on behaviour. For example, haloperidol is a
selective and strong antagonist of the dopamine-2 (D2) re-
ceptor; blockage of striatal D2-receptor is associated with
antipsychotic effect. However, haloperidol use in TBI has
been associated with prolonged post-traumatic amnesia in
humans and was detrimental to motor and cognitive recov-
ery in pre-clinical models of TBI [32–34, 39]. Dopamine re-
ceptor blocking in the mesocortical and nigrostriatal
pathways is thought to be involved in these adverse effects.
Atypical antipsychotics also inhibit the D2 receptor but are
also antagonists of other receptors such as the serotonin 2A
receptor. These agents have been extensively studied in the
treatment of agitation in psychiatric disorders and are often
considered for the treatment of agitation in TBI because of
their improved safety profile [40, 41]. Pre-clinical animal
studies have suggested that olanzapine does not disrupt
cognitive recovery following TBI whereas risperidone may
hasten recovery [32, 42]. Neurostimulants such as methyl-
phenidate increase dopamine and norepinephrine availability
whereas amantadine increases dopaminergic neurotransmis-
sion. As dopamine plays a role in behavioural regulation and
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arousal, possibly through frontal lobe stimulation, increasing
its availability may be beneficial in the management of agita-
tion. Anticonvulsants (i.e., valproic acid, carbamazepine,
levetiracetam, lamotrigine, gabapentin) are clinically used
as mood stabilizers in bipolar affective disorder and have
been used in TBI-associated agitation [23, 43]. Among
potential mechanisms, they are thought to act by inhibit-
ing GABA. Agitation is also very frequently treated with
benzodiazepines, which act by stimulating the gamma
subunit of the GABA-A receptor causing sedation, or less
frequently with antidepressants [44]. Antidepressants such
as SSRIs act by increasing availability of serotonin and
have been studied for agitated behaviour [45, 46].
Why is it important to do this review?
As post-traumatic agitation is a complex and poorly
understood complication, occurring in a heterogeneous pa-
tient population, pharmacological interventions are inad-
equately studied despite the frequent use of various
medications [27, 28]. Given the desired impact on the
resolution of agitation while limiting potential adverse ef-
fects associated with the use of these agents in the TBI
population, an analysis of the literature evaluating their effi-
cacy and safety is imperative. The last Cochrane systematic
review was published in 2006, only included randomized
controlled trials and didn’t include studies specifically evalu-
ating safety outcomes [47]. Recent systematic reviews on
agitation and behaviour disorders following TBI published
by the French Society of Physical and Rehabilitation
Medicine evaluated English and French language studies
published between 1990 and 2015 identified through a
MEDLINE search [48, 49]. Other important databases
(EMBASE, CINAHL, PsychInfo, LILACS, DOAJ) as well as
studies published in other languages and the grey literature
were not searched. Hence, there is a need for an updated
knowledge synthesis in this area that will inform treatment
algorithms, provide guidance for clinicians, identify know-
ledge gaps, and ultimately guide future research protocols
and knowledge translation opportunities. We anticipate this
review will allow us to draw important conclusions on the
relative safety and efficacy of agents in current use for agita-
tion following a TBI. This will provide clinicians with a more
complete knowledge base and minimize the uncertainty sur-
rounding the available evidence for the use of pharmaco-
logical intervention for agitation in the TBI population.
Review question
What are the most effective and safest pharmacological ther-
apies for the management of agitation in TBI patients?
Methods/design
Type of studies
We will include all randomized controlled, quasi-
experimental, and observational studies with control
groups. We will exclude case reports, case series, and ob-
servational studies without a control group. The checklist
of the PRISMA-P recommendations is included as an
additional file (see Additional file 1). The review protocol
has been registered in PROSPERO international prospect-
ive register of systematic reviews (CRD42016033140)
Types of participants
The population of interest is all patients, including chil-
dren (ages 0 to 18) and adults, who have suffered a TBI.
We will include TBI patients in both the early stages of
recovery and in rehabilitation. Finally, we will include all
studies that have a majority (>50%) of patients with TBI.
Types of interventions
We will include studies evaluating the use of pharmaco-
logical interventions in which agitation, not further defined,
was the presenting symptom or one of the presenting symp-
toms. We will also include studies where agitation was not
the presenting symptom but was measured as an outcome
variable; such studies will be analysed separately. We will
also include studies specifically assessing the safety of
pharmacological agents used for agitation in traumatic brain
injury. Studies evaluating all pharmacological interventions
including beta-adrenergic blockers, typical and atypical anti-
psychotics, anticonvulsants (i.e., valproic acid, carbamaze-
pine, oxcarbazepine, levetiracetam, gabapentin), dopamine
agonists (amantadine), psychostimulants (i.e., methylphenid-
ate), antidepressants, alpha-2-adrenergic agonists (clonidine,
dexmedetomidine), and hypnotics and anxiolytics (benzodi-
azepines) will be included. Studies comparing these agents
to either a placebo, an active treatment, or a non-
pharmacological intervention will be included. Studies
comparing drugs within a pharmacological class will also be
included.
Types of outcome measures
The primary outcome measure will be a reduction in sever-
ity of agitation. When feasible, we will report resolution of
agitation as well as changes in duration and type of symp-
toms (confusion, aggressiveness, inattention, hallucinations,
disorientation, and inappropriate mood or speech).
Secondary outcomes include length of stay (ICU length
of stay for the acute phase and hospital LOS for the
rehabilitation phase), adverse events (i.e., confusion, para-
doxical agitation, lethargy, depression, drowsiness, disin-
hibition, dizziness, insomnia, tremor, extrapyramidal
effects, seizures, arrhythmia, bradycardia or tachycardia,
hypotension or hypertension, respiratory depression, nau-
sea or vomiting, constipation, urinary retention, sexual
dysfunction, or any other unanticipated adverse effects),
use of physical restraints, cognitive function (as defined by
the study authors), and functional outcome (as defined by
the study authors).
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Search methods for identification of studies
The search strategy aims at identifying all eligible studies re-
gardless of publication status or language. The investigators,
with the help of Health Sciences librarian with expertise in
systematic reviews, will design the search strategy using the
Peer Review for Electronic Search Strategies (PRESS) check-
list and conduct the search (see Additional file 2) [50]. The
following databases will be searched: PubMed, Ovid
MEDLINE®, Ovid MEDLINE®, In-Process & Other Non-
Indexed Citations, EMBASE, CINAHL, PsycINFO,
Cochrane Library, Google Scholar, Directory of Open Ac-
cess Journals, LILACS, Web of Science and Prospero
(http://www.crd.york.ac.uk/PROSPERO/).
Searching other sources
A grey literature search will be performed using the
resources suggested in CADTH’s Grey Matters (http://
www.cadth.ca/en/resources/finding-evidence-is/grey-mat-
ters). We will manually search abstracts from annual sci-
entific meetings of the following relevant groups in the
last 3 years: the International Brain Injury Association,
North American Brain Injury Society, Trauma Association
of Canada, Neurocritical Care Society, National Neuro-
trauma Society, American Congress of Rehabilitation
Medicine, American Psychiatric Association, European
Psychiatric Association, Society of Critical Care Medicine,
European Society of Intensive Care Medicine, Inter-
national Symposium on Intensive Care and Emergency
Medicine, American Delirium Society, American Thoracic
Society, CHEST, and Australia New Zealand Intensive
Care Society. We will also search for unpublished and on-
going trials at clinicaltrials.gov using the term “traumatic
brain injury”. Finally, references of identified studies as
well as other types of articles (reviews, book chapters) will
be screened.
Data collection and analysis
Two independent authors (DW, AJF) will screen the titles
and/or abstracts of identified publications for eligibility.
Eligible citations will be read in full-text version by mul-
tiple pairs of two independent authors and evaluated for
inclusion using the eligibility criteria. Disagreements will
be resolved by consensus and discussion with a third re-
viewer (FB) when needed. Following the literature search,
an EndNote database (EndNote version X7.5.3 Thomson
Reuteurs, New York) will be used to manage search
results.
Data extraction and management
Data from all included studies will be extracted inde-
pendently and in duplicate using a pre-tested data ex-
traction form. The following variables will be recorded
for each study: the study title, the name of the first
author, the year of publication, the country of origin,
language of publication, type of publication (journal art-
icle, conference proceeding, abstract, thesis), type of set-
ting (intensive care unit, hospital ward, rehabilitation
unit), type of study (randomized controlled, blinded or
open, non-randomized controlled, prospective or retro-
spective), study population (paediatric, adult), patient’s
characteristics (age, gender, number, isolated TBI or
multiple trauma including TBI, days from TBI at inclu-
sion, inclusion and exclusion criteria), characteristics of
the intervention and control treatment (type of pharmaco-
logical agent, dose, frequency and duration of the therapy),
and outcomes (intensity, duration and type of symptoms,
length of stay, adverse events, use of physical restraints,
cognitive function, and functional outcome). If needed, we
(DW) will contact the corresponding authors of the in-
cluded studies up to three times for clarifications.
Assessment of risk of bias
Two reviewers will independently evaluate each included
study with an appropriate evaluation tool. In the case of
disagreement concerning the risk of bias, a third reviewer
(FB) will be consulted to resolve the issue. Randomized
controlled trials and observational studies will be evalu-
ated with the Cochrane Collaboration and Ottawa-
Newcastle tools, respectively [51, 52]. The risk of bias of
randomized controlled trials using the Cochrane Collabor-
ation tool assesses the quality of studies according to six
domains: random sequence allocation, allocation conceal-
ment, blinding, incomplete outcome data, and selective
reporting. Once the evaluation is complete, randomized
controlled trials will be assigned to one of three categories
(low risk of bias, moderate risk of bias, and high risk of
bias) as suggested by the Cochrane Collaboration [51].
The Ottawa-Newcastle tool assesses the quality of obser-
vational studies according to the following criteria:
representativeness of the exposed cohort, selection of the
non-exposed cohort, ascertainment of exposure, demon-
stration that the outcome of interest was not present at
the start of the study, the comparability of cohorts on the
basis of the design or analysis, outcome assessment
methods, and the adequacy of the follow-up. A score of a
maximum of nine points is attributed to each study.
The risk of bias assessments will aid in the overall
evaluation of the quality of the evidence and enable the
evaluation of the impact of bias on the findings. We plan
to include all randomized controlled trials and observa-
tional studies regardless of their risk of bias. The risk of
bias categories for randomized controlled trials and the
scores for observational studies will be reported in the
final publication.
Statistical analysis
The results of the systematic review will be initially pre-
sented as a descriptive overview with the results of
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observational studies presented separately from those of
randomized controlled trials. Sensitivity analysis will be
performed to evaluate the effects of the different
pharmacological classes, age groups (<18 and ≥18 years),
stages of recovery (early recovery and rehabilitation),
and study type (observational versus randomized). We will
qualitatively evaluate the studies for heterogeneity by
comparing pharmacological classes, drug doses, allowed
co-therapies (antipsychotics, sedatives, analgesics), use of
physical restraints, clinical setting, and number of study
sites. We will qualitatively evaluate methodological
heterogeneity (study design, risk of bias, type of control
group). We expect to observe important clinical and
observational heterogeneity in the studies that will be
identified. In the absence of important clinical and meth-
odological heterogeneity, we will analyse the study results
for statistical heterogeneity, using the I2 and the chi-
square (p < 0.1 will be considered statistically significant).
If the statistical heterogeneity is acceptable (I2 < 50%), we
will proceed to a meta-analysis of the data using Review
Manager (RevMan 5.3) software (Nordic Cochrane Center,
Cochrane Collaboration). As the methods are very differ-
ent, observational studies and randomized controlled trials
will be analysed separately. Observational studies, using
adjusted odds ratios, and randomized controlled trials will
be analysed with a random effect model that will be used
if at least two studies are available. Continuous results will
be presented as differences of means with 95% confidence
intervals. Categorical results will be presented as odds ra-
tios with 95% confidence intervals. If the number of iden-
tified studies is sufficient, we will conduct subgroup
analysis according to pharmacological classes, clinical set-
ting (intensive care unit and hospital ward versus rehabili-
tation unit), and risk of bias. Randomized controlled trials
with a high risk of bias and observational studies with a
score below six will be compared to studies with a low or
moderate risk of bias and a score of six or greater, respect-
ively. A trained statistician with prior experience in meta-
analyses will perform the statistical analyses.
Discussion
Although agitation is frequent following TBI and
pharmacological agents that are often used, there is no
consensus on the most efficacious and safest strategy to
treat these complications. In fact, the Society of Critical
Care Medicine, the Neurobehavioral Guidelines Working
Group, and the Brain Trauma Foundation guidelines offer
no specific recommendations [53–55]. Whereas, the Inter-
national Traumatic Brain Injury Cognitive Rehabilitation
Guidelines (INCOG) suggest the avoidance of neuroleptics
because of pre-clinical studies suggesting potential harm
[29]. The last Cochrane Systematic Review was published in
2006 and no new review is underway [47]. Recently
published systematic reviews on agitation and behaviour
disorders following TBI by the French society of physical
and rehabilitation medicine evaluated studies between 1990
and 2015 [48, 49]. These recent systematic reviews identified
studies solely through a MEDLINE search, restricted
languages to English and French, and did not search grey lit-
erature. The exclusion of other databases in which many
journals are not indexed in MEDLINE (EMBASE, CINAHL,
PsychInfo, LILACS, DOAJ) and the restriction of publica-
tions in other languages than English or French may have
limited the findings. In addition, adding the grey literature
to a systematic review has been shown to increase studies in
Cochrane reviews. As there are possible unidentified studies,
there is a need for an updated systematic review evaluating
all the possible sources including the grey literature, all
major databases, and to summarize the evidence in order to
inform practice and future research.
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